Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the NIH. Read more >>